THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.
Initial Public Offer of equity shares on the main board of BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE", and together with BSE, the "Stock Exchanges") in compliance with Chapter IIA of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations").

molbio®
INNOVATE • IMPACT • INSPIRE

(Please scan this QR code to view the Prospectus)

MOLBIO DIAGNOSTICS LIMITED

(TO BE LISTED ON THE MAIN BOARD OF BSE AND NSE)

Our Company was originally incorporated as 'Molbio Diagnostics Private Limited' at Panaji, as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 20, 2000, issued by the RoC. Thereafter, our Company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the extraordinary general meeting of our Shareholders held on November 22, 2024, and the name of our Company was changed to 'Molbio Diagnostics Limited', and a fresh certificate of incorporation dated January 16, 2025 was issued to our Company by the RoC. For further details on the changes in the name and registered office of our Company, see "History and Certain Corporate Matters – Brief history of our Company" and "*History and Certain Corporate Matters – Change in registered office of our Company*" on page 246 of the prospectus dated August 12, 2026 ("**Prospectus**") filed with the RoC.

Registered and Corporate Office: Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa - 403 722, Goa, India. **Contact Person**: Darshan Raghunath Karekar, Company Secretary and Compliance Officer;
Telephone: +91 832 6724888; **Email**: investors@molbiodiagnostics.com; **Website**: www.molbiodiagnostics.com; **Corporate Identity Number**: U33125GA2000PLC002909

OUR PROMOTERS: SRIRAM NATARAJAN, DR. CHANDRASEKHAR BHASKARAN NAIR, SANGEETHA SRIRAM, SHIVA SRIRAM, SOWMYA SRIRAM AND EXXORA TRADING LLP

Our Company has filed the Prospectus with the RoC, dated August 12, 2026 and the Equity Shares (as defined below) are proposed to be listed on the main board platform of the Stock Exchanges and the trading will commence on Monday, August 17, 2026.

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFERING OF 11,646,246* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH OF OUR COMPANY ("EQUITY SHARES") FOR CASH AT A PRICE OF ₹ 807.00 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ 806.00 PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING TO ₹ 9,396.96 MILLION^ ("OFFER"). THE OFFER COMPRISES A FRESH ISSUE OF 2,480,246* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 2,000^ MILLION ("FRESH ISSUE") AND AN OFFER FOR SALE OF 9,166,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH ("OFFERED SHARES") AGGREGATING TO ₹ 7,396.96 MILLION, COMPRISING 1,811,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 1,461.48 MILLION BY EXXORA TRADING LLP, 1,221,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 985.35 MILLION BY DR. CHANDRASEKHAR BHASKARAN NAIR (JOINTLY HELD WITH ANITA ANGELA CHANDRASEKHAR), 48,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 38.74 MILLION BY ABDUL QADIR MOHAMED THERUVATH, 193,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 155.75 MILLION BY CHEWBACCA SERVICES LIMITED, 902,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 727.91 MILLION BY J. GURU DUTT (JOINTLY HELD WITH SANDHYA GURU DUTT), 1,125,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 907.88 MILLION BY GOPALKRISHNA MANGALORE KINI, 902,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 727.91 MILLION BY GOPALAKRISHNA SAMPATHGIRI (JOINTLY HELD WITH JAYSHREE SAMPATHGIRI), 1,000,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 807.00 MILLION BY INDIA BUSINESS EXCELLENCE FUND III, 17,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 13.72 MILLION BY M GANESH KAMATH, 248,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 200.14 MILLION BY M.A. ROHIT, 202,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 163.01 MILLION BY M.A. SHARATH, 451,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 363.96 MILLION BY M.A. USHA RANI, 452,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 364.76 MILLION BY SANGEETHA M KINI, 97,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 78.28 MILLION BY SHAHEEDA ABDUL KADER, 226,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 182.38 MILLION BY SHRUTHI G KINI, 193,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 155.75 MILLION BY SUJAY LIMITED, AND 78,000* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 62.95 MILLION BY VIVEK DEVARAJ (TOGETHER, THE "SELLING SHAREHOLDERS", AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE").

**** Subject to finalization of Basis of Allotment. ^ A discount of ₹ 76 per Equity Share was offered to Eligible Employees bidding in the Employee Reservation Portion.***

THIS OFFER INCLUDED A RESERVATION OF 20,519* EQUITY SHARES OF FACE VALUE OF ₹ 1 EACH AGGREGATING TO ₹ 15.00^ MILLION (CONSTITUTING 0.02% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WOULD CONSTITUTE 10.11% AND 10.09%, RESPECTIVELY, OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL.

**** Subject to finalization of Basis of Allotment. ^ Net of Employee Discount***

ANCHOR INVESTOR OFFER PRICE: ₹807 PER EQUITY SHARE OF FACE VALUE OF ₹1 EACH
OFFER PRICE: ₹807 PER EQUITY SHARE OF FACE VALUE OF ₹1 EACH
THE OFFER PRICE IS 807 TIMES THE FACE VALUE OF THE EQUITY SHARES.

RISK TO INVESTORS

(For details, refer to section titled "Risk Factors" on page 28 of the Prospectus)

1. **Customer Concentration Risk:** We derive a portion of our revenues from the sale of our products to the Indian Central and State governments, and international aid agencies for their public healthcare programs, and from our top 10 customers. Any unfavourable policy changes, a decrease in funding for public healthcare programs, the loss of such customers, a decrease in demand for our products, failure to negotiate commercial terms, disputes, adverse change in financial condition, price reductions, variation in demand, or inability to maintain historic levels of business or reduce customer concentration could have an adverse impact on our business and results of operations. The table below sets forth our revenues generated from such government and international aid agencies and non-government agencies for the years indicated:

Revenue from contracts with customers	Fiscal 2026		Fiscal 2025		Fiscal 2024	
	Amount (in ₹ million)	Percentage of Revenue from contracts with customers - Sale of products - Finished Goods (%)	Amount (in ₹ million)	Percentage of Revenue from contracts with customers - Sale of products - Finished Goods (%)	Amount (in ₹ million)	Percentage of Revenue from contracts with customers - Sale of products - Finished Goods (%)
Sale of products - Finished Goods from Indian Central government	7,906.52	56.52%	4,998.20	50.81%	2,757.97	33.83%
Sale of products - Finished Goods from Indian State governments	3,257.73	23.29%	2,101.54	21.36%	4,153.07	50.94%
Sale of products - Finished Goods from International aid agencies*	664.52	4.75%	1,540.04	15.66%	556.47	6.83%
Sale of products - Finished Goods from non-government agencies	2,159.48	15.44%	1,197.48	12.17%	684.87	8.40%
Sale of products-Finished Goods	**13,988.25**	**100.00%**	**9,837.26**	**100.00%**	**8,152.38**	**100.00%**

**International aid agencies include organizations that provide assistance, both humanitarian and developmental, to countries and populations in need around the world which includes governmental, intergovernmental, or non-governmental organisations (NGOs). Our arrangements with international aid agencies typically involve framework agreements or understandings for supply of products. These agreements do not include firm commitments regarding the quantity of devices or test kits to be procured. Instead, purchase orders are placed by these agencies on a need basis, depending on their program requirements.*

The table below sets forth our revenues from our top 10 customers, expressed as a percentage of revenue from contracts with customers - sale of products - finished goods for the years indicated.

Customers	Fiscal 2026		Fiscal 2025		Fiscal 2024	
	Amount (in ₹ million)	Percentage of Revenue from contracts with customers - Sale of products - Finished Goods (%)	Amount (in ₹ million)	Percentage of Revenue from contracts with customers - Sale of products - Finished Goods (%)	Amount (in ₹ million)	Percentage of Revenue from contracts with customers - Sale of products - Finished Goods (%)
Top One	7,906.52	56.52%	4,998.20	50.81%	2,757.97	33.83%
Top Five	10,328.01	73.83%	7,375.18	74.97%	5,079.46	62.31%
Top Ten	11,647.31	83.26%	8,225.64	83.62%	6,402.78	78.54%

2. **Product revenue concentration risk**: As of March 31, 2026, we offer molecular testing covering 30 diseases, including tuberculosis ("**TB**"), COVID, Hepatitis B and C, HIV, and Human Papillomavirus ("**HPV**") through 43 assays. Our revenue from the sale of test kits for TB was 70.20%, 69.11% and 62.40% of our revenue from contracts with customers - sale of products - finished goods in the Fiscals 2026, 2025 and 2024, respectively. Any decline in the demand for such Test Kits for TB, have an adverse effect on our business and financial condition.

3. **R&D Execution Risk**: We have invested and intend to continue to invest in research and development efforts which are undertaken through our wholly-owned Subsidiary, Bigtec Private Limited to grow our menu of tests. Developing new tests and assays takes substantial time and requires substantial technical, financial and human resources. The success of any new test or assays will depend on several factors, including our ability to demonstrate the accuracy and usability of the tests, obtain necessary regulatory clearances and approvals and produce new tests in commercial quantities at an acceptable cost. The table below sets forth details of our expenses towards R&D in the years indicated:

Particulars	Fiscal 2026		Fiscal 2025		Fiscal 2024	
	Amount (₹ million)	Percentage of revenue from operations (%)	Amount (₹ million)	Percentage of revenue from operations (%)	Amount (₹ million)	Percentage of revenue from operations (%)
Research and Development spends	874.56	6.05%	685.69	6.72%	597.77	7.15%

4. **Losses and negative cash flow from operating activities in the past**: Our Subsidiaries, Prognosys Medical Systems Private Limited, Prognosys Healthcare (India) Private Limited and OptraScan INC, have incurred losses in the past and may incur losses in the future. Further, our Company (on a consolidated basis) and some of our Subsidiaries, Prognosys Medical Systems Private Limited, Prognosys Healthcare (India) Private Limited and OptraScan INC have experienced negative cash flows from operating activities in the past. The table sets forth details of profit/ (losses) after tax of certain of our Subsidiaries for the years indicated:

Subsidiary	Fiscal 2026	Fiscal 2025	Fiscal 2024
	(₹ in million)		
Bigtec Private Limited	275.67	188.65	94.77
Prognosys Medical Systems Private Limited(1)	119.90	(45.17)	(224.49)
Prognosys Healthcare (India) Private Limited	(7.03)	1.60	(18.69)
OptraScan INC	(111.42)	NA	NA
OptraScan India Private Limited(2)	1.97	NA	NA

Note: The figures have been considered from the respective standalone financial statements before consolidation adjustments / eliminations.

(1) During Fiscal 2024, we acquired 54.54% shareholding in Prognosys Healthcare (India) Private Limited and the same is consolidated from the date of acquiring control. Since Prognosys Healthcare (India) Private Limited became our Subsidiary with effect from July 26, 2023, the profit/ (losses) after tax of ₹(18.69) million in Fiscal 2024 mentioned above represents its profit/(losses) after tax for approximately eight months. In March 2023, we acquired, directly and indirectly, 65.47% of the equity share capital of Prognosys Medical Systems Private Limited. Subsequently, in April 2026, we acquired an additional stake in Prognosys Medical Systems Private Limited, increasing our shareholding to 70.00% of its equity share capital.

(2) In October 2024, our Company entered into a stock purchase agreement to invest and hold 60.00% of the paid-up equity share capital of OptraScan INC. On November 5, 2024, our Company received the share certificate in respect of the first tranche investment, acquiring 19.68% of the equity share capital of OptraScan INC. As on November 1, 2025, our Company made the second tranche investment, acquiring an additional 40.32% equity stake in OptraScan INC. Pursuant to the aforesaid, OptraScan INC and OptraScan India Private Limited became our Subsidiaries with effect from November 1, 2025. The respective profit/(loss) after tax of these two entities in Fiscal 2026 represents their profit/(loss) after tax from November 1, 2025 to March 31, 2026.

5. **Promoters Interest Risk**: Our Promoters (certain of whom are also Directors, Key Managerial Personnel and members of our Senior Management) are interested in our Company, in addition to regular remuneration or benefits and reimbursement of expenses payable to them by our Company or Subsidiaries.

6. **Royalty payable to Bigtec**: Our Company has entered into an IP agreement with Bigtec, pursuant to which Bigtec has granted our Company an unconditional, irrevocable, exclusive, transferable, royalty bearing, worldwide and unlimited right to use and exploit the intellectual property rights and is required to pay a security deposit of up to ` 2,000.00 million in regular intervals which shall be adjusted against 10% of our revenue from operations, payable every year as royalty to Bigtec, for a period of 15 years from the date of the agreement. Pursuant to an addendum dated July 25, 2026, the term of the IP Agreement was extended by one year with effect from August 1, 2026, pursuant to which the royalty payable by our Company is capped at up to 10% of its topline revenue for the relevant financial year. The table below sets forth the royalty expenses to Bigtec for the years indicated:

Particulars	Fiscal 2026	Fiscal 2025	Fiscal 2024
	(₹ in million)		
Royalty expense	1,233.62	929.59	739.28

7. **Intellectual Property and Proprietary Information Risk**: If we are unable to patent new processes and protect our proprietary information or other intellectual property, our business may be adversely affected. We rely on a combination of trademark, patents and designs, confidentiality procedures, cybersecurity practices and contractual provisions to protect our intellectual property rights.

8. **Auditor Observations and findings**: Our Statutory Auditors' audit reports on our audited consolidated financial statements for Fiscals 2026, 2025 and 2024 includes emphasis of matter paragraph, modifications for certain matters specified in the report on other legal and regulatory requirements and certain qualifications under the reporting requirements under the Companies (Auditor's Report) Order, 2020 and Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended). Moreover, the Statutory Auditor's reports on internal financial controls issued on our audited consolidated financial statements for Fiscal 2024 contain a disclaimer of opinion relating to the Statutory Auditors' inability to obtain appropriate audit evidence to provide a basis for opinion on adequate internal financial controls.

9. **Risk Relating to Objects of the Offer and its utilization**: We intend to utilize a portion of the Net Proceeds for funding our capital expenditure requirements towards (i) the setting up of infrastructure for a research and development facility and Center of Excellence and connected office space for our Company, Subsidiaries and Associate and (ii) purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit. However, We are yet to place orders or enter into any definitive agreements towards the proposed capital expenditure requirements and have relied on quotations received from third parties for estimation of the cost. Our Company has entered into an IP agreement with Bigtec, pursuant to which royalty is payable every year to Bigtec. One of our Objects, will be used for setting up of infrastructure for a research and development facility and Center of Excellence for Bigtec.

10. **Capacity underutilization Risk**: Underutilization of our manufacturing capacities over extended periods, or significant under-utilization in the short term, could increase could limit our ability to leverage our economies of scale, our cost of production and our operating costs which could have an adverse impact our business, growth prospects. The table below sets out our overall capacity utilization for the years indicated.

Products*	Fiscal 2026	Fiscal 2025	Fiscal 2024
	Capacity Utilisation(1)		
Truenat Device	42.30%	58.89%	19.83%
Truenat Test Kits	58.25%	43.44%	27.45%
Xray devices	50.71%	19.23%	11.62%
Digital Pathology Scanner	27.50%	Not applicable(2)	Not applicable(2)

**As certified by Multi Engineers Private Limited, an independent chartered engineer, by certificate dated July 24, 2026.*

(1) Capacity utilization has been calculated on the basis of actual production in the relevant Fiscal divided by the installed capacity during such Fiscal.

(2) OptraScan India Private Limited, which manufacturers digital pathology scanners, became our Subsidiary with effect from November 1, 2025

11. **Regulatory Compliance and approval Risk**: Our operations are subject to extensive government regulation and if we fail to obtain, maintain or renew our statutory and regulatory licenses, permits and approvals required to operate our business, results of operations and cash flows may be adversely affected. Further, any adverse regulatory action may restrict us from effectively marketing and selling our products, may limit our ability to obtain future premarket clearances or approvals and could result in a substantial modification to our business practices and operations.

12. **The Price/Earnings Ratio based on basic and diluted EPS for Financial Year 2026 for the Company at the upper end of the price band is 54.64. The average Industry group Price / Earnings ratio is 64.89.**

13. **Weighted Average Return on Net Worth for Financial Years ended 2026, 2025 and 2024 is 14.46%.**

14. **The average cost of acquisition of Equity Shares for Selling Shareholders ranges from ₹ Nil per Equity Share to ₹ 187.14 per Equity Share and the Offer Price at upper end of the Price Band is ₹ 807 per Equity Share.**

15. **Weighted average cost of acquisition of all shares transacted in the 1 year, 18 months and 3 years preceding the date of the Prospectus.**

Period*	Weighted average cost of acquisition per equity share (in ₹)^	Cap Price is 'x' times the weighted average cost of acquisition	Range of acquisition price per equity share: lowest price – highest price (in ₹)^
Last one year	810.87	1.00	807.00 - 1,090.00
Last 18 months	927.34	0.87	807.00 - 1,108.00
Last three years	909.89	0.89	130.29 - 1,108.00

** As certified by B.B. & Associates, Chartered Accountants, by way of their certificate dated August 12, 2026*

^ Pursuant to resolutions passed by our Board and the Shareholders in their respective meetings held on July 5, 2024, and July 10, 2024, respectively the authorised share capital of our Company was sub divided from 12,200,000 equity shares of face value of ₹ 10 each to 122,000,000 Equity Shares of face value ₹ 1 each. Accordingly, the issued, subscribed and paid-up equity share capital of our Company was sub-divided from 2,253,660 equity shares of face value of ₹ 10 per equity share to 22,536,600 Equity Shares of face value of ₹1 per Equity Share. Our Company has allotted bonus shares on July 29, 2025, in the ratio of 4 Equity Shares for every Equity Share held. The weighted average cost of acquisition has been adjusted to reflect the impact of the split and the bonus issue.

16. **The 4 BRLMs associated with the issue have handled 100 public issues in the past three years out of which 29 issues closed below the issue price on listing date.**

Name of the BRLMs	Total Public Issues	Issues closed below the issue price on listing date
Kotak Mahindra Capital Company Limited	17	5
IIFL Capital Services Limited *(formerly known as IIFL Securities Limited)*	26	10
Jefferies India Private Limited	5	-
Motilal Oswal Investment Advisors Limited	18	5
Common issues handled by the BRLMs*	34	9
Total	**100**	**29**

**Issues handled where there were no common BRLMs.*

Continued to next page...

...continued from previous page.

BID/OFFER PERIOD:

ANCHOR INVESTOR BID/OFFER PERIOD OPENED AND CLOSED ON: FRIDAY, AUGUST 7, 2026
BID/OFFER OPENED ON: MONDAY, AUGUST 10, 2026
BID/OFFER CLOSED ON: WEDNESDAY, AUGUST 12, 2026

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contract (Regulation) Rules, 1957 ("**SCRR**") read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("**QIBs**", and such portion, the "**QIB Portion**"), provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis ("**Anchor Investor Portion**"), out of which 40% shall be available for allocation as follows: (i) 33.33% for domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from the domestic Mutual Funds and Life Insurance Companies and Pension Funds, at or above the price at which allocation will be made to Anchor Investors ("**Anchor Investor Allocation Price**") in accordance with the SEBI ICDR Regulations. Any under-subscription in the portion amounting to 6.67% reserved for Life Insurance Companies and Pension Funds may be allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) (the "**Net QIB Portion**"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, subject to valid Bids being received at or above the Offer Price, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to all QIBs. Further, not less than 15% of the Net Offer shall be available for allocation to Non-Institutional Bidders (out of which one-third of the portion available to Non-Institutional Bidders shall be reserved for Bidders with an application size of more than ₹ 0.20 million and up to ₹ 1.00 million and two-thirds shall be reserved for Bidders with an application size of more than ₹ 1.00 million, provided that the unsubscribed portion in either of the aforementioned sub-categories may be allocated to Bidders in the other sub-category) and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All Bidders, other than Anchor Investors, are required to participate in the Offer by mandatorily utilising the Application Supported by Blocked Amount ("**ASBA**") process by providing details of their respective ASBA Account (as defined hereinafter) and UPI ID in case of UPI Bidders (as defined hereinafter), as applicable, pursuant to which their corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("**SCSBs**") or by the Sponsor Banks under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For further details, see "***Offer Procedure***" on page 488 of the Prospectus.

The bidding for Anchor Investors opened and closed on Friday, August 7, 2026. The company received 33 Anchor Investor Application Forms from 16 Anchor Investors (including 9 domestic mutual funds through 19 Mutual Fund schemes) for 3,655,674 Equity Shares. The Anchor investor price was finalized at ₹ 807 per Equity Share. A total of 3,487,717 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 2,814,587,619/-.

The Offer received 2,696,330 applications for 577,496,304 Equity Shares (prior to rejections) resulting in 49.59 times subscription. The details of the applications received in the Offer from various categories are as under: (before rejections):

Sl. No.	Category	No. of Applications received	No. of Equity Shares applied	No. of Equity Shares reserved as per Prospectus	No. of times Subscribed	Amount (₹)
A	Retail Individual Investors	2,533,001	53,061,876	4,069,005	13.04	42,816,847,914.00
B	Non-Institutional Investors - More than ₹0.20 million up to ₹1.00 million	107,700	28,050,858	581,287	48.26	22,631,993,028.00
C	Non-Institutional Investors - Above ₹1.00 million	46,583	59,381,946	1,162,573	51.08	47,920,768,974.00
D	Eligible Employees	8,874	271,890	20,519	13.25	198,740,430.00
E	Qualified Institutional Bidders (excluding Anchors Investors)	139	433,074,060	2,325,145	186.26	349,490,766,420.00
F	Anchor Investors	33	3,655,674	3,487,717	1.05	2,950,128,918.00
	Total	**2,696,330**	**577,496,304**	**11,646,246**	**49.59**	**466,009,245,684.00**

** This excludes 12,732 applications for 260,298 Equity Shares aggregating to ₹209,698,884/- from Retail Individual & HNI Individuals which were not in bid book but which were banked.*

Final Demand

A summary of the final demand as per BSE and NSE as on the Bid/Offer Closing Date and as at different Bid prices is as under:

Sr. No.	Bid Price (₹)	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1	768	72,972	0.01	72,972	0.01
1	769	3,762	0.00	76,734	0.01
1	770	12,600	0.00	89,334	0.02
2	771	774	0.00	90,108	0.02
3	772	846	0.00	90,954	0.02
4	773	90	0.00	91,044	0.02
5	774	432	0.00	91,476	0.02
6	775	7,002	0.00	98,478	0.02
7	776	1,836	0.00	100,314	0.02
8	777	2,250	0.00	102,564	0.02
9	778	3,096	0.00	105,660	0.02
10	779	144	0.00	105,804	0.02
11	780	15,732	0.00	121,536	0.02
12	781	288	0.00	121,824	0.02
13	782	90	0.00	121,914	0.02
14	783	144	0.00	122,058	0.02
15	784	36	0.00	122,094	0.02
16	785	2,880	0.00	124,974	0.02
17	786	1,152	0.00	126,126	0.02
18	787	1,350	0.00	127,476	0.02
19	788	3,348	0.00	130,824	0.02
20	789	612	0.00	131,436	0.02
21	790	15,678	0.00	147,114	0.03
22	791	558	0.00	147,672	0.03
23	792	414	0.00	148,086	0.03
24	793	2,790	0.00	150,876	0.03
25	794	1,818	0.00	152,694	0.03
26	795	2,538	0.00	155,232	0.03
27	796	450	0.00	155,682	0.03
28	797	432	0.00	156,114	0.03
29	798	234	0.00	156,348	0.03
30	799	1,746	0.00	158,094	0.03
31	800	22,716	0.00	180,810	0.03
32	801	9,162	0.00	189,972	0.03
33	802	8,028	0.00	198,000	0.03
34	803	9,576	0.00	207,576	0.04
35	804	6,228	0.00	213,804	0.04
36	805	34,182	0.01	247,986	0.04
37	806	51,588	0.01	299,574	0.05
38	807	532,267,830	91.25	532,567,404	91.30
	CUTOFF	50,721,984	8.70	583,289,388	100.00
	Total	**583,289,388**	**100.00**		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE on August 13, 2026.

A. Allotment to Retail Individual Investors (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Retail Individual Investors, who have bid at the Cut-Off Price or at the Offer Price of ₹ 807 per Equity Share, was finalized in consultation with the BSE. This category has been subscribed to the extent of 12.65 times. The total number of Equity Shares Allotted in Retail Portion is 4,069,005 Equity Shares to 226,055 successful Retail Individual Investors. The category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	18	2,322,160	94.62	41,798,880	81.22	18	7 : 76	3,849,894
2	36	67,291	2.74	2,422,476	4.71	18	7 : 76	111,564
3	54	21,898	0.89	1,182,492	2.30	18	7 : 76	36,306
4	72	8,990	0.37	647,280	1.26	18	7 : 76	14,904
5	90	8,662	0.35	779,580	1.51	18	7 : 76	14,364
6	108	3,853	0.16	416,124	0.81	18	7 : 76	6,390
7	126	4,273	0.17	538,398	1.05	18	7 : 76	7,074
8	144	1,157	0.05	166,608	0.32	18	7 : 76	1,908
9	162	865	0.04	140,130	0.27	18	7 : 76	1,440
10	180	2,623	0.11	472,140	0.92	18	7 : 76	4,356
11	198	610	0.02	120,780	0.23	18	7 : 76	1,008
12	216	620	0.03	133,920	0.26	18	7 : 76	1,026
13	234	11,314	0.46	2,647,476	5.14	18	7 : 76	18,756
	36 to 234 (Allottees)	0	0.00	-	0.00	1	15 : 12172	15
	TOTAL	**2,454,316**	**100.00**	**51,466,284**	**100.00**			**4,069,005**

Please Note : 1 additional Share shall be allotted to 15 Allottees from amongst 12,172 Successful Allottees from all the Categories (excluding category 18) in the ratio of 15 : 12172

B. Allotment to Non-Institutional Investors (More than ₹0.20 million Up to ₹1.00 million) (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Investors (more than ₹0.20 million Up to ₹1.00 million), who have bid at the Offer Price of ₹ 807 per Equity Share or above, was finalized in consultation with BSE. This category has been subscribed to the extent of 47.49 times. The total number of Equity Shares allotted in this category is 581,287 Equity Shares to 2,306 successful applicants. The category-wise details of the Basis of Allotment are as under: **(Sample)**

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	252	100,802	95.08	25,402,104	92.02	252	173 : 7952	552,636
2	270	1,781	1.68	480,870	1.74	252	39 : 1781	9,828
3	288	595	0.56	171,360	0.62	252	13 : 595	3,276
4	306	305	0.29	93,330	0.34	252	7 : 305	1,764
5	324	215	0.20	69,660	0.25	252	5 : 215	1,260
6	342	77	0.07	26,334	0.10	252	2 : 77	504
7	360	300	0.28	108,000	0.39	252	7 : 300	1,764
8	378	136	0.13	51,408	0.19	252	3 : 136	756
9	396	37	0.03	14,652	0.05	252	1 : 37	252
10	414	30	0.03	12,420	0.04	252	1 : 30	252
11	432	36	0.03	15,552	0.06	252	1 : 36	252
12	450	86	0.08	38,700	0.14	252	2 : 86	504
22	630	179	0.17	112,770	0.41	252	4 : 179	1,008
23	648	31	0.03	20,088	0.07	252	1 : 31	252
24	666	9	0.01	5,994	0.02	252	0 : 9	0
25	684	8	0.01	5,472	0.02	252	0 : 8	0
26	702	5	0.00	3,510	0.01	252	0 : 5	0
27	720	30	0.03	21,600	0.08	252	1 : 30	252
28	738	8	0.01	5,904	0.02	252	0 : 8	0
29	756	55	0.05	41,580	0.15	252	1 : 55	252
30	774	7	0.01	5,418	0.02	252	0 : 7	0
48	1098	3	0.00	3,294	0.01	252	0 : 3	0
49	1116	7	0.01	7,812	0.03	252	0 : 7	0
50	1134	7	0.01	7,938	0.03	252	0 : 7	0
51	1152	1	0.00	1,152	0.00	252	0 : 1	0
52	1170	7	0.01	8,190	0.03	252	0 : 7	0
53	1188	4	0.00	4,752	0.02	252	0 : 4	0
54	1206	5	0.00	6,030	0.02	252	0 : 5	0
55	1224	149	0.14	182,376	0.66	252	3 : 149	756
	270 to 1224 (Allottees)	-	0.00	-	0.00	1	1 : 1	113
	270 to 1224 (Allottees)	-	0.00	-	0.00	1	62 : 113	62
	TOTAL	**106,015**	**100.00**	**27,605,718**	**100.00**			**581,287**

Please Note: 1 additional Share shall be allocated to all 113 Successful Allottees from all the Categories (excluding the Category 252) in the ratio of 1 : 1

Please Note: 1 additional Share shall be allocated to all 113 Successful Allottees from all the Categories (excluding the Category 252) in the ratio of 62 : 113

C. Allotment to Non-Institutional Investors (more than ₹1.00 million) (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Investors (more than ₹1.00 million), who have bid at the Offer Price of ₹ 807 per Equity Share or above, was finalized in consultation with BSE. This category has been subscribed to the extent of 50.69 times. The total number of Equity Shares allotted in this category is 1,162,573 Equity Shares to 4,613 successful applicants. The category-wise details of the Basis of Allotment are as under: **(Sample)**

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	1242	44,139	95.48	54,820,638	93.03	252	49 : 491	1,110,060
2	1260	936	2.02	1,179,360	2.00	252	93 : 936	23,436
3	1278	138	0.30	176,364	0.30	252	14 : 138	3,528
4	1296	226	0.49	292,896	0.50	252	23 : 226	5,796
5	1314	73	0.16	95,922	0.16	252	7 : 73	1,764
113	12996	1	0.00	12,996	0.02	252	0 : 1	0
114	13500	2	0.00	27,000	0.05	252	0 : 2	0
115	15480	2	0.00	30,960	0.05	252	0 : 2	0
116	18000	2	0.00	36,000	0.06	252	0 : 2	0
123	55800	1	0.00	55,800	0.09	252	0 : 1	0
124	100008	2	0.00	200,016	0.34	252	0 : 2	0
125	200016	1	0.00	200,016	0.34	252	0 : 1	0
	Non Allottees	-	0.00	-	-	252	10 : 147	2,520
	All Allottees	-	0.00	-	-	1	97 : 4613	97
	TOTAL	**46,229**	**100.00**	**58,927,014**	**100.00**			**1,162,573**

Please Note : 1 (One) lot of 252 shares have been allocated to all the 147 Non Allottees Applicants in Categories with Zero/No Allotment in the ratio of 10 : 147

Please Note : 1 additional Share shall be allocated to 97 Allottees from amongst 4613 Successful Allottees from all the categories in the ratio of 97 : 4613

D. Allotment to Employee Reservation (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Eligible Employee Portion, who have bid at the Offer Price of ₹ 731* per Equity Share was finalized in consultation with BSE. This category has been subscribed to the extent of 2.54 times. The total number of Equity Shares allotted in this category is 20,519 Equity Shares to 469 successful applicants. The category-wise details of the Basis of Allotment are as under:

** A discount of ₹ 76 per Equity Share was offered to Eligible Employees bidding in the Employee Reservation Portion.*

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	18	156	33.26	2,808	7.03	18	80 : 156	1,440
2	36	83	17.70	2,988	7.48	18	1 : 1	1,494
	36	0	0.00	0	0.00	1	37 : 83	37
3	54	48	10.23	2,592	6.49	28	1 : 1	1,344
4	72	40	8.53	2,880	7.21	37	1 : 1	1,480
5	90	13	2.77	1,170	2.93	46	1 : 1	598
6	108	8	1.71	864	2.16	55	1 : 1	440
7	126	17	3.62	2,142	5.36	65	1 : 1	1,105
8	144	17	3.62	2,448	6.13	74	1 : 1	1,258
9	162	4	0.85	648	1.62	83	1 : 1	332
10	180	5	1.07	900	2.25	92	1 : 1	460
11	198	2	0.43	396	0.99	102	1 : 1	204
12	216	3	0.64	648	1.62	111	1 : 1	333
13	234	6	1.28	1,404	3.52	120	1 : 1	720
14	252	2	0.43	504	1.26	129	1 : 1	258
15	270	65	13.86	17,550	43.94	138	1 : 1	8,970
	270	0	0.00	0	0.00	1	46 : 65	46
	TOTAL	**469**	**100.00**	**39,942**	**100.00**			**20,519**

Note : 50 Applications from Above 2 Lakhs Categories have been added to Category 270 (upto 2 Lakhs Category) initially having 15 Applications for the purpose of proportionate Allotment.

Note : 1 additional share has been allocated to Category 36 and 270 in the ratio of 37:83 and 46:65

E. Allotment to QIB portion (After Rejections)

Allotment to QIBs, who have Bid at the Offer Price of ₹ 807 per Equity Share or above, has been done on a proportionate basis in consultation with the BSE. This category has been subscribed to the extent of 186.26 times of Net QIB Portion. As per the SEBI ICDR Regulations, Mutual Funds were allotted 5% of the Equity Shares of Net QIB Portion available i.e., 116,258 Equity Shares and other QIBs and unsatisfied demand of Mutual Funds were Allotted the remaining available Equity Shares i.e., 2,208,887 Equity Shares on a proportionate basis. The total number of Equity Shares Allotted in the QIB Portion is 2,325,145 Equity Shares which were allotted to 370 successful QIB Investors. The category-wise details of the Basis of Allotment are as under:

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FII-FPI	OTHERS	TOTAL
Allotment	994,587	238,105	69,838	-	-	876,497	146,118	**2,325,145**

F. Allotment to Anchor Investors

The Company, in consultation with the BRLMs, have allocated 3,487,717 Equity Shares to 16 Anchor Investors (through 33 Applications) at the Anchor Investor Offer Price of ₹ 807 per Equity Share in accordance with the SEBI Regulations. This represents 60% of the QIB Portion.

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPC/FPI	INS	PF	OTHERS	TOTAL
Allotment	-	2,354,490	265,789	-	-	867,438	-	-	-	**3,487,717**

The Board of Directors of our Company at its meeting held on August 13, 2026 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being BSE and has allotted the Equity Shares to various successful Bidders. The Allotment Advice-cum-Intimations and/or notices have been dispatched to the address of the investors as registered with the depositories. Further, the instructions to the Self Certified Syndicate Banks for unblocking of funds, transfer to Public Offer Account have been issued on August 13, 2026 and payment to non-Syndicate brokers have been issued on August 14, 2026. In case the same is not received within ten days, investors may contact the Registrar to the Offer at the address given below. The Equity Shares Allotted to the successful Allottees have been uploaded on August 14, 2026 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company has filed the Listing application with BSE and NSE on August 14, 2026. The Company has received listing and trading approval from BSE and NSE and the trading will commence on August 17, 2026.

Note: All capitalized terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus.

INVESTORS PLEASE NOTE

The details of the allotment made will be hosted on the website of the Registrar to the Offer, KFin Technologies Limited at www.kfintech.com

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/sole Bidder, Bid cum Application Form number, Bidder DP ID, Client ID, PAN, date of submission of Bid-cum-Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the Designated Intermediary at the address given below:

KFINTECH

KFin Technologies Limited
Selenium, Tower B, Plot 31 - 32, Financial District, Nanakramguda, Serilingampally Mandal
Hyderabad - 500 032, Telangana, India]
Telephone: +91 40 6716 2222 / 1800 3094001
Email: molbio.ipo@kfintech.com
Investor grievance email: einward.ris@kfintech.com
Website: www.kfintech.com
Contact person: M Murali Krishna
SEBI Registration No: INR000000221

For **MOLBIO DIAGNOSTICS LIMITED**
On behalf of the Board of Directors
Sd/-
Darshan Raghunath Karekar
Company Secretary and Compliance Officer

Place: Goa, India
Date: August 14, 2026

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF MOLBIO DIAGNOSTICS LIMITED.

MOLBIO DIAGNOSTICS LIMITED has filed the Prospectus dated August 12, 2026 with RoC and the Stock Exchanges. The Prospectus is available on the website of SEBI at www.sebi.gov.in, and is available on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.molbiodiagnostics.com and the websites of the BRLMs, i.e. Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited *(formerly known as IIFL Securities Limited)*, Jefferies India Private Limited and Motilal Oswal Investment Advisors Limited at https://investmentbank.kotak.com, www.iiflcapital.com, www.jefferies.com and www.motilaloswal.com, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "*Risk Factors*" beginning on page 28 of the Prospectus.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**U.S. Securities Act**") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in "offshore transactions" as defined in and in reliance on, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made.